A photo of Peter de Blank.

Co-Medical Director, Brain Tumor Center

Associate Professor, UC Department of Pediatrics

513-517-2068

Board Certified

Best Doctors logo

My Biography & Research

Biography

Dr. de Blank graduated from the University of California, San Francisco School of Medicine with a concentration in Medical Education. He completed his residency in Pediatrics, and fellowships in Pediatric Hematology & Oncology and Pediatric Neuro-Oncology at the Children’s Hospital of Philadelphia. He completed a Masters of Science in Clinical Epidemiology and Biostatistics at the University of Pennsylvania during his fellowship training. After completing his training, he became a faculty member at University Hospitals Rainbow Babies & Children’s Hospital in Cleveland in 2012. In 2017, Dr. de Blank joined the faculty at Cincinnati Children’s Hospital Medical Center as a member of the Pediatric Neuro-Oncology program.

Dr. de Blank’s clinical and research interests include children with central nervous system tumors, neurofibromatosis type 1 (NF1), and NF1-related tumors. His research focuses on the investigation of tissue microstructure in pediatric brain tumors through non-invasive imaging techniques such as MR relaxometry and diffusion tensor imaging. The goal of his research is to develop early radiographic tumor biomarkers to characterize pediatric brain tumors and predict their functional consequences. Tumor imaging research may guide early intervention efforts and direct support for children with brain tumors in order to improve clinical outcomes in children with brain tumors.

Dr. de Blank has been elected by peers for inclusion in the Best Doctors in America List.

Clinical Interests

Pediatric neuro-oncology; neurofibromatosis type 1 (NF1); NF1-associated brain tumors

Research Interests

Cancer imaging; diffusion tensor imaging; MR relaxometry; magnetic resonance fingerprinting; developmental therapeutics

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Brain Tumor, Rasopathy, Neurofibromatosis

Research Divisions

Cancer and Blood Diseases, Oncology

My Locations

My Education

BA: Stanford University, Stanford, CA, 1997.

BS: Chemistry, Stanford University, Stanford, CA, 1997.

MA: Stanford University, Stanford, CA, 1997.

MD: Emphasis in Medical Education, University of California, San Francisco School of Medicine, San Francisco, CA, 2005.

MS: Clinical Epidemiology, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 2011.

Intern: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2005-2006.

Resident: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2006-2008.

Fellow: Pediatric Hematology and Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2008-2011; Pediatric Neuro-Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2011-2012.

My Publications

Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. de Blank, P; Li, N; Fisher, MJ; Ullrich, NJ; Bhatia, S; Yasui, Y; Sklar, CA; Leisenring, W; Howell, R; Oeffinger, K; et al. Genetics in Medicine. 2020; 22:1794-1802.

Molecular markers and targeted therapy in pediatric low-grade glioma. de Blank, P; Fouladi, M; Huse, JT. Journal of Neuro-Oncology. 2020; 150:5-15.

A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). DeWire, M; Fuller, C; Hummel, TR; Chow, LM L; Salloum, R; de Blank, P; Pater, L; Lawson, S; Zhu, X; Dexheimer, P; et al. Journal of Neuro-Oncology. 2020; 149:511-522.

Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations. de Blank, P; Berman, JI; Prelack, M; Sollee, JR; Lane, A; Waldman, AT; Fisher, MJ. 2020; 2:i150-i158.

Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor. Lazow, MA; Lawson, SA; Salloum, R; Hummel, TR; Pillay Smiley, N; DeWire-Schottmiller, MD; Fouladi, M; de Blank, P. Journal of Pediatric Hematology/Oncology. 2020; Publish Ahead of Print.

Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Fangusaro, J; Witt, O; Driever, PH; Bag, AK; de Blank, P; Kadom, N; Kilburn, L; Lober, RM; Robison, NJ; Fisher, MJ; et al. The Lancet Oncology. 2020; 21:e305-e316.

Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies. Gilligan, LA; DeWire-Schottmiller, MD; Fouladi, M; DeBlank, P; Leach, JL. American Journal of Neuroradiology. 2020; 41:866-873.

Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1. Bhatia, S; Chen, Y; Wong, FL; Hageman, L; Smith, K; Korf, B; Cannon, A; Leidy, DJ; Paz, A; Andress, JE; et al. Journal of Clinical Oncology. 2019; 37:3050-3058.

Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors. de Blank, P; Badve, C; Gold, DR; Stearns, D; Sunshine, J; Dastmalchian, S; Tomei, K; Sloan, AE; Barnholtz-Sloan, JS; Lane, A; et al. Pediatric Neurosurgery. 2019; 54:310-318.

Management of pediatric low-grade glioma. de Blank, P; Bandopadhayay, P; Haas-Kogan, D; Fouladi, M; Fangusaro, J. Current Opinion in Pediatrics. 2019; 31:21-27.